PL2694037T3 - Formulacje zawierające 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol - Google Patents

Formulacje zawierające 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol

Info

Publication number: PL2694037T3
Authority: PL; Poland
Prior art keywords: octylphenyl; diol; propane; formulations; ethyl
Prior art date: 2011-04-01

Application number

PL12714163T

Other languages

English (en)

Inventor

Supriya Rane

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2012-03-30

Publication date

2017-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2694037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-03-30 Application filed by Novartis Ag filed Critical Novartis Ag

2017-05-31 Publication of PL2694037T3 publication Critical patent/PL2694037T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Transplantation (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

PL12714163T 2011-04-01 2012-03-30 Formulacje zawierające 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol PL2694037T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161470747P	2011-04-01	2011-04-01
US201161545835P	2011-10-11	2011-10-11
EP12714163.8A EP2694037B1 (en)	2011-04-01	2012-03-30	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

Publications (1)

Publication Number	Publication Date
PL2694037T3 true PL2694037T3 (pl)	2017-05-31

Family

ID=45953284

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL12714163T PL2694037T3 (pl)	2011-04-01	2012-03-30	Formulacje zawierające 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol
PL16176665T PL3143990T3 (pl)	2011-04-01	2012-03-30	Formulacje zawierające 2-amino-2-[2-(4- oktylofenylo)etylo]propano-1,3-diol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16176665T PL3143990T3 (pl)	2011-04-01	2012-03-30	Formulacje zawierające 2-amino-2-[2-(4- oktylofenylo)etylo]propano-1,3-diol

Country Status (35)

Country	Link
US (5)	US9592208B2 (pl)
EP (2)	EP2694037B1 (pl)
JP (1)	JP6019101B2 (pl)
KR (1)	KR102027014B1 (pl)
CN (1)	CN103476400B (pl)
AR (1)	AR085749A1 (pl)
AU (1)	AU2012236357B2 (pl)
BR (1)	BR112013024430B1 (pl)
CA (1)	CA2831600C (pl)
CL (1)	CL2013002810A1 (pl)
CO (1)	CO6771459A2 (pl)
CY (2)	CY1118423T1 (pl)
DK (2)	DK2694037T3 (pl)
EA (2)	EA027721B1 (pl)
EC (1)	ECSP13012912A (pl)
ES (2)	ES2610966T3 (pl)
GT (1)	GT201300227A (pl)
HK (1)	HK1190309A1 (pl)
HR (2)	HRP20170021T1 (pl)
HU (1)	HUE031286T2 (pl)
IL (1)	IL228250B (pl)
JO (1)	JO3177B1 (pl)
LT (2)	LT2694037T (pl)
MA (1)	MA34981B1 (pl)
MX (1)	MX342522B (pl)
MY (2)	MY175633A (pl)
PE (2)	PE20140162A1 (pl)
PL (2)	PL2694037T3 (pl)
PT (2)	PT2694037T (pl)
RS (1)	RS59917B1 (pl)
SG (1)	SG193256A1 (pl)
SI (2)	SI3143990T1 (pl)
TW (1)	TWI528958B (pl)
WO (1)	WO2012135561A1 (pl)
ZA (1)	ZA201306636B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014141298A2 (en) *	2013-03-11	2014-09-18	Astron Research Limited	Stable pharmaceutical composition of fingolimod
CN103222966A (zh) *	2013-04-01	2013-07-31	北京万全德众医药生物技术有限公司	一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
EP3027174B1 (en)	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Pharmaceutical compositions of fingolimod
US20170231928A1 (en) *	2014-08-22	2017-08-17	Sunshine Lake Pharma Co., Ltd.	Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en)	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
JP2018502168A (ja) *	2015-01-20	2018-01-25	ハンダファーマシューティカルズエルエルシー	安定な固体フィンゴリモド剤形
WO2018178744A1 (en)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Stable formulations of fingolimod
WO2021158848A1 (en) *	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor agonist
US11135197B2 (en)	2020-02-07	2021-10-05	Argentum Pharmaceuticals Llc	Dosage regimen of an S1P receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
EP0627406B1 (en)	1992-10-21	1998-10-28	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es)	1995-12-28	2005-05-01	Mitsubishi Pharma Corporation	`composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JPH11209277A (ja)	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
IL131608A (en)	1997-02-27	2003-02-12	Welfide Corp	Pharmaceutical composition and kit containing the same
ATE298740T1 (de)	1997-04-04	2005-07-15	Mitsubishi Pharma Corp	2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja)	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
JP2004507552A (ja)	2000-08-31	2004-03-11	メルク　エンド　カムパニー　インコーポレーテッド	免疫調節剤としてのリン酸誘導体
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
US20040048877A1 (en) *	2002-05-22	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions containing flibanserin
KR101367574B1 (ko) *	2003-04-08	2014-02-25	미쓰비시 타나베 파마 코퍼레이션	Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
WO2005025553A2 (en) *	2003-09-12	2005-03-24	Neuronova Ab	Treatment of disorders of nervous systemsystem with fty720
US7888527B2 (en)	2004-12-06	2011-02-15	University Of Virginia Patent Foundation	Aryl amide sphingosine 1-phosphate analogs
GB0502358D0 (en) *	2005-02-04	2005-03-16	Novartis Ag	Organic compounds
GT200600350A (es)	2005-08-09	2007-03-28		Formulaciones líquidas
TWI389683B (zh)	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2748432T3 (es) *	2006-09-26	2020-03-16	Novartis Ag	Composiciones farmacéuticas que comprenden un modulador de S1P
CL2007003784A1 (es)	2006-12-21	2008-06-27	Abbott Lab	Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
TW200927142A (en) *	2007-10-12	2009-07-01	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP2012508215A (ja)	2008-11-11	2012-04-05	ノバルティスアーゲー	有機化合物
US20100160259A1 (en)	2008-12-22	2010-06-24	Robert Schmouder	Dosage regimen for a s1p receptor agonist

2012
- 2012-03-29 JO JOP/2012/0074A patent/JO3177B1/ar active
- 2012-03-29 AR ARP120101074A patent/AR085749A1/es not_active Application Discontinuation
- 2012-03-30 PT PT127141638T patent/PT2694037T/pt unknown
- 2012-03-30 EA EA201391442A patent/EA027721B1/ru not_active IP Right Cessation
- 2012-03-30 PE PE2013002121A patent/PE20140162A1/es active IP Right Grant
- 2012-03-30 WO PCT/US2012/031340 patent/WO2012135561A1/en active Application Filing
- 2012-03-30 EP EP12714163.8A patent/EP2694037B1/en active Active
- 2012-03-30 LT LTEP12714163.8T patent/LT2694037T/lt unknown
- 2012-03-30 EA EA201790436A patent/EA035686B1/ru not_active IP Right Cessation
- 2012-03-30 EP EP16176665.4A patent/EP3143990B1/en active Active
- 2012-03-30 KR KR1020137025398A patent/KR102027014B1/ko active IP Right Grant
- 2012-03-30 CN CN201280017346.1A patent/CN103476400B/zh active Active
- 2012-03-30 ES ES12714163.8T patent/ES2610966T3/es active Active
- 2012-03-30 MA MA36277A patent/MA34981B1/fr unknown
- 2012-03-30 US US14/009,241 patent/US9592208B2/en active Active
- 2012-03-30 HU HUE12714163A patent/HUE031286T2/hu unknown
- 2012-03-30 PE PE2017000900A patent/PE20170913A1/es not_active Application Discontinuation
- 2012-03-30 DK DK12714163.8T patent/DK2694037T3/en active
- 2012-03-30 JP JP2014502817A patent/JP6019101B2/ja active Active
- 2012-03-30 MY MYPI2017000050A patent/MY175633A/en unknown
- 2012-03-30 MX MX2013011415A patent/MX342522B/es active IP Right Grant
- 2012-03-30 CA CA2831600A patent/CA2831600C/en active Active
- 2012-03-30 BR BR112013024430-5A patent/BR112013024430B1/pt active IP Right Grant
- 2012-03-30 AU AU2012236357A patent/AU2012236357B2/en active Active
- 2012-03-30 ES ES16176665T patent/ES2773482T3/es active Active
- 2012-03-30 LT LTEP16176665.4T patent/LT3143990T/lt unknown
- 2012-03-30 PL PL12714163T patent/PL2694037T3/pl unknown
- 2012-03-30 PL PL16176665T patent/PL3143990T3/pl unknown
- 2012-03-30 MY MYPI2013003216A patent/MY163746A/en unknown
- 2012-03-30 SI SI201231732T patent/SI3143990T1/sl unknown
- 2012-03-30 RS RS20200141A patent/RS59917B1/sr unknown
- 2012-03-30 SI SI201230821A patent/SI2694037T1/sl unknown
- 2012-03-30 TW TW101111547A patent/TWI528958B/zh active
- 2012-03-30 DK DK16176665.4T patent/DK3143990T3/da active
- 2012-03-30 PT PT161766654T patent/PT3143990T/pt unknown
- 2012-03-30 SG SG2013065867A patent/SG193256A1/en unknown
2013
- 2013-09-02 IL IL228250A patent/IL228250B/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06636A patent/ZA201306636B/en unknown
- 2013-09-27 CO CO13230722A patent/CO6771459A2/es unknown
- 2013-09-27 GT GT201300227A patent/GT201300227A/es unknown
- 2013-09-30 CL CL2013002810A patent/CL2013002810A1/es unknown
- 2013-10-01 EC ECSP13012912 patent/ECSP13012912A/es unknown
2014
- 2014-04-09 HK HK14103389.7A patent/HK1190309A1/zh unknown
2017
- 2017-01-09 HR HRP20170021TT patent/HRP20170021T1/hr unknown
- 2017-01-12 CY CY20171100045T patent/CY1118423T1/el unknown
- 2017-01-30 US US15/418,831 patent/US20170135967A1/en not_active Abandoned
2018
- 2018-03-09 US US15/916,371 patent/US20180193291A1/en not_active Abandoned
2019
- 2019-04-23 US US16/391,506 patent/US20190247335A1/en not_active Abandoned
2020
- 2020-02-14 HR HRP20200249TT patent/HRP20200249T1/hr unknown
- 2020-02-24 CY CY20201100169T patent/CY1122868T1/el unknown
- 2020-05-18 US US16/876,336 patent/US20200276137A1/en not_active Abandoned

Also Published As

Publication number	Publication date
LT2694037T (lt)	2017-01-10
MY175633A (en)	2020-07-02
SI2694037T1 (sl)	2017-01-31
EA201391442A1 (ru)	2014-04-30
EA201790436A3 (ru)	2018-03-30
MA34981B1 (fr)	2014-03-01
EA035686B1 (ru)	2020-07-27
PL3143990T3 (pl)	2020-05-18
LT3143990T (lt)	2020-02-25
CN103476400B (zh)	2016-11-09
MX342522B (es)	2016-10-03
PT2694037T (pt)	2017-01-17
US20190247335A1 (en)	2019-08-15
DK2694037T3 (en)	2017-01-16
CL2013002810A1 (es)	2014-02-14
KR20140014194A (ko)	2014-02-05
IL228250B (en)	2020-09-30
PT3143990T (pt)	2020-03-04
DK3143990T3 (da)	2020-03-02
US20170135967A1 (en)	2017-05-18
US9592208B2 (en)	2017-03-14
NZ615023A (en)	2016-07-29
CO6771459A2 (es)	2013-10-15
EP2694037B1 (en)	2016-10-12
EA027721B1 (ru)	2017-08-31
MY163746A (en)	2017-10-31
HUE031286T2 (hu)	2017-06-28
BR112013024430B1 (pt)	2022-02-08
AU2012236357A1 (en)	2013-10-10
WO2012135561A1 (en)	2012-10-04
CA2831600A1 (en)	2012-10-04
TW201244711A (en)	2012-11-16
HK1190309A1 (zh)	2014-07-04
EP3143990A1 (en)	2017-03-22
ECSP13012912A (es)	2013-11-29
EP3143990B1 (en)	2019-11-27
CN103476400A (zh)	2013-12-25
JP6019101B2 (ja)	2016-11-02
ES2773482T3 (es)	2020-07-13
CY1118423T1 (el)	2017-06-28
BR112013024430A2 (pt)	2016-12-20
JP2014509652A (ja)	2014-04-21
US20180193291A1 (en)	2018-07-12
SG193256A1 (en)	2013-10-30
US20200276137A1 (en)	2020-09-03
EA201790436A2 (ru)	2017-10-31
JO3177B1 (ar)	2018-03-08
MX2013011415A (es)	2013-12-09
KR102027014B1 (ko)	2019-09-30
PE20170913A1 (es)	2017-07-12
AU2012236357B2 (en)	2016-03-10
SI3143990T1 (sl)	2020-03-31
RS59917B1 (sr)	2020-03-31
CY1122868T1 (el)	2021-05-05
US20140371323A1 (en)	2014-12-18
EP2694037A1 (en)	2014-02-12
TWI528958B (zh)	2016-04-11
GT201300227A (es)	2015-05-05
PE20140162A1 (es)	2014-02-12
HRP20170021T1 (hr)	2017-03-10
ES2610966T3 (es)	2017-05-04
ZA201306636B (en)	2014-05-28
HRP20200249T1 (hr)	2020-05-15
AR085749A1 (es)	2013-10-23
CA2831600C (en)	2020-04-21

Publication	Publication Date	Title
HRP20200249T1 (hr)	2020-05-15	Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
EP2774912A4 (en)	2015-07-29	CATIONIC LIPID
HK1199798A1 (en)	2015-07-24	Heated insoles
BR112013008597A2 (pt)	2017-07-25	fornecimento de mercado para serviços de software
EP2768921A4 (en)	2015-08-26	REFRIGERANT PREPARATIONS
GB201403204D0 (en)	2014-04-09	Heel protector
EP2755680A4 (en)	2015-04-15	PARTICULATE VACCINE FORMULATIONS
GB201114725D0 (en)	2011-10-12	Ophthalmic formulations
IL208019A0 (en)	2010-12-30	Process for the preparation of 2-amino-2-[2-(4-c3-c21-alkyl-phenyl) ethyl) propane-1, 3-diols
PT2686011T (pt)	2017-11-23	Vacina contra npi
BR112013015953A2 (pt)	2018-07-10	processo para a preparação de sais de cis-1-amônio-4-alcoxiciclohexanocarbonitrilo.
ZA201305986B (en)	2014-10-29	Improved insecticide formulations
EP2771854A4 (en)	2015-06-24	SYSTEM TO OFFER ON ADVERTISING CONTENT
ZA201306475B (en)	2014-05-28	Solid herbicidal composition comprising mesotrione
GB2494389B (en)	2015-02-18	Rotor blade
GB201120001D0 (en)	2012-01-04	Herbicide applicator
BR112013012799A2 (pt)	2016-09-13	enantiômemero ativo de dodecil 2-(n,n-dimetilamino)-propionato
SMT201600415B (it)	2017-01-10	Procedimento di preparazione di metaxalone
GB201120994D0 (en)	2012-01-18	Integral stiffener
ES1074764Y (es)	2011-09-27	Protector para espatulas.
PL395428A1 (pl)	2013-01-07	Srodek do wypelniania zwlaszcza otworowych wymienników ciepla
ES1074718Y (es)	2011-08-30	Protector para cordones de calzado.
GB201101410D0 (en)	2011-03-16	Heated shoe